Ribonucleases for treating viral infections
AssigneeOrgenesis Inc.
InventorsJAMIE SULLEY, LUIS SQUIQUERA, THOMAS HODGE, SABINA GLOZMAN, Vered CAPLAN
Life of this patent
Estimating the term…
Abstract
This disclosure is directed to compounds and pharmaceutical compositions for treating and preventing viral diseases, as Covid-19. Among others, the invention relates to the use of ribonucleases and bioxoms, exosomes or combination thereof in the preparations and use of pharmaceutical formulations for the treatment of said disease. In addition, the invention relates to the use of immune cells and ribonucleases in the preparation and use of pharmaceutical formulations for the treatment of said disease.
Claims22
A composition comprising a ribonuclease and a bioxome, an exosome or a combination thereof.
A method for treating a viral disease in a subject in need thereof, the method comprising administering a composition comprising a ribonuclease and a bioxome, an exosome or a combination thereof.
(canceled)
(canceled)
A method for treating or preventing a viral disease in a subject, comprising administering a composition, wherein said composition comprises a ribonuclease and wherein said composition is loaded into a bioxome, an exosome, or a combination thereof.
A method for treating or preventing a viral disease in a subject, comprising administering a composition, wherein said composition comprises a ribonuclease and wherein said composition is administered with a bioxome, an exosome, or a combination thereof.
Dependencies are inferred from the claim text.